Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 29 of 29 results for abiraterone

  1. NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.

    data on the effectiveness of enzalutamide after previous treatment with abiraterone. Any explanatory notes(if applicable) The use of...

    Research recommendation
    Published
    9 June 2015

  2. NICE impact prostate cancer

    Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer

  3. NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and overall survival.

    relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and...

    Research recommendation
    Published
    9 June 2015

  4. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044

    Awaiting development [GID-TA11558] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA404

  6. Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523

    Awaiting development [GID-TA11114] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued [GID-TA10465]

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development [GID-TA10696] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Past appeals and decisions

    for erythropoietic protoporphyria [ID927] 15 May 2023 TA721 Abiraterone for treating newly diagnosed high risk metastatic hormone-naive...

  10. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

    Technology appraisal guidance
    Published
    15 November 2023
    View recommendations

    Sections for TA930

  11. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development [GID-TA10779] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    In development [GID-TA11252] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Research recommendations

    data on the effectiveness of enzalutamide after previous treatment with abiraterone. TA316/1

  14. Behind the Headlines - Prostate cancer drug decision a 'cruel twist'

    We take a closer look at media coverage that claims our prostate cancer drug decision is a 'cruel twist' for patients.

    News
    Published
    4 February 2014